10 Dividend Stocks That Will Double Your Money


Is it possible to double your money – quickly – buying safe dividend stocks? You bet. Let me explain how…

“Basic” income investors are enamored with higher current yields. These are OK for payouts today, but they’re not going to get us 100%+ gains.

For triple-digit profits we must pay attention to the underrated dividend hike. These raises not only increase the yield on your initial investment, but they trigger stock price increases, too.

For example, if a stock pays a 3% current yield and then hikes its payout by 10%, it’s unlikely that its stock price will stagnate for long. Investors will see the new 3.3% yield and buy more shares. They’ll drive the price up, and the yield back down – eventually towards 3%.

This is why many Dividend Aristocrats don’t pay high current yields: Their prices just rise too fast. Just look at A.O. Smith (NYSE:AOS), which perpetually yields in the low 1% range. The low yield isn’t from a lack of dividend hikes – in fact, AOS keeps hiking its payout more aggressively over time. But investors just keep chasing the stock too high!


What a “problem” to have!

If you’re looking for a “dividend stock double” to bring you secure gains of 100% or better, consider these ten payers. Don’t be fooled by their modest current yields – these dividends will probably always look modest thanks to soaring share prices.



Continue reading ...


In case you interested of stock analysis of other bloggers, click on link below:



Analysis Collection

The Top 11 Big Pharma Dividend Stocks Ranked By Total Return


Drug companies are often considered defensive in nature due to their stable earnings, through good economies and bad. People with illnesses or diseases will likely seek out treatments to improve their quality of life, regardless of the condition of the economy.

The high cost of life saving or improving medicines means that pharmaceutical companies often generate huge amounts of cash flow, which allows them to pay high dividend yields. Even in a recession, many of these companies are able to keep paying and raising dividends due to the large amount of cash on the balance sheet.

For all these reasons, pharmaceutical stocks are strong candidates for a dividend growth portfolio.This article examines 11 of the largest pharmaceutical stocks in detail. All 11 stocks pay dividends, and can be found on our list of 203 dividend-paying healthcare stocks.


The list is ranked by their total annual expected return over the next five years. Rankings are determined by expected annual return, based on the stock’s current yield, valuation changes, and earnings growth. All stocks can be found in the Sure Analysis Research Database.





In case you interested of stock analysis of other bloggers, click on link below:



Analysis Collection

Sell Now: 3 Blue Chips with Slowing Dividend Growth


Bigger isn’t always better when it comes to dividends. Deutsche Bank recently pointed out “the first half of 2018 has seen the sharpest underperformance of dividend stocks since the financial crisis”, as measured by the Dividend Aristocrats.

Most readers are already familiar with this group of 53 names within the S&P 500 index, many paying out billions of dividends each quarter, with the most common trait being they’ve each boosted payouts a minimum of 25 consecutive years.

However, another item several of the Aristocrats share in common, is that the Law of Large Numbers is catching up to them. They may be paying out more to investors each year, but as my colleague Brett Owens has often pointed out, it’s how much the dividend is growing that is the best predictor for building wealth over time.


This is especially the case when interest rates are rising. An annual payout increase of a penny or two may produce a positive headline and keep you in the Aristocrat club another year, but these three names are barely treading water against other income investments and certainly not keeping up with the 7.2% average year-to-date dividend growth in the S&P 500.


Continue reading …


In case you interested of stock analysis of other bloggers, click on link below:



Analysis Collection


Notable Analyst Upgrades and Downgrades for Week of July 9, 2018



Upgrades:


Archer Daniels Midland (NYSE:ADM) was upgraded by stock analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a report released on Monday, MarketBeat.com reports. The brokerage presently has a $48.00 price target on the stock, up from their previous price target of $42.00. JPMorgan Chase & Co.’s price target indicates a potential upside of 0.13% from the stock’s current price. Other research analysts have also issued research reports about the stock. ValuEngine lowered shares of Archer Daniels Midland from a “buy” rating to a “hold” rating in a report on Wednesday, May 2nd. Zacks Investment Research lowered shares of Archer Daniels Midland from a “buy” rating to a “hold” rating in a report on Tuesday, May 8th. Goldman Sachs Group upgraded shares of Archer Daniels Midland from a “neutral” rating to a “buy” rating and raised their price objective for the company from $43.30 to $50.00 in a report on Monday, March 12th. Citigroup raised their price objective on shares of Archer Daniels Midland from $53.00 to $54.00 and gave the company a “buy” rating in a report on Wednesday, May 2nd. Finally, Monness Crespi & Hardt upgraded shares of Archer Daniels Midland from a “sell” rating to a “neutral” rating in a report on Wednesday, May 2nd. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $45.92. Read more …

Canadian National Railway (NYSE:CNI) (TSE:CNR) was upgraded by equities researchers at Deutsche Bank from a “hold” rating to a “buy” rating in a research note issued to investors on Monday, The Fly reports. CNI has been the subject of a number of other research reports. Stifel Nicolaus began coverage on Canadian National Railway in a report on Thursday, May 24th. They issued a “hold” rating and a $84.00 price target for the company. Zacks Investment Research raised Canadian National Railway from a “strong sell” rating to a “hold” rating in a report on Tuesday, May 1st. Macquarie cut Canadian National Railway from an “outperform” rating to a “neutral” rating in a report on Thursday, May 17th. They noted that the move was a valuation call. Cowen upped their price target on Canadian National Railway from $86.00 to $87.00 and gave the stock an “outperform” rating in a report on Tuesday, April 24th. Finally, Deutsche Bank raised Canadian National Railway from a “sell” rating to a “hold” rating and set a $81.00 price target for the company in a report on Thursday, May 24th. Ten analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $84.98. Read more …

Raymond James upgraded shares of Canadian Pacific Railway (TSE:CP) (NYSE:CP) from an outperform rating to a strong-buy rating in a report issued on Monday. They currently have C$275.00 price target on the stock, up from their previous price target of C$260.00. Other equities research analysts have also recently issued research reports about the stock. Desjardins lowered their target price on shares of Canadian Pacific Railway from C$254.00 to C$253.00 in a report on Monday, April 16th. BMO Capital Markets boosted their target price on shares of Canadian Pacific Railway from C$254.00 to C$265.00 in a report on Thursday, June 28th. National Bank Financial boosted their target price on shares of Canadian Pacific Railway from C$250.00 to C$260.00 and gave the company a sector perform rating in a report on Thursday, June 21st. CIBC boosted their target price on shares of Canadian Pacific Railway from C$263.00 to C$270.00 in a report on Thursday, April 19th. Finally, Royal Bank of Canada boosted their target price on shares of Canadian Pacific Railway from C$256.00 to C$258.00 and gave the company an outperform rating in a report on Thursday, April 19th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Canadian Pacific Railway presently has an average rating of Buy and an average price target of C$259.25. Read more …



Cummins (NYSE:CMI) was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating in a report released on Tuesday, Marketbeat reports. The firm currently has a $160.00 price objective on the stock, down from their previous price objective of $174.00. Stifel Nicolaus’ price objective points to a potential upside of 19.32% from the company’s previous close. CMI has been the subject of several other reports. Buckingham Research downgraded shares of Cummins from a “buy” rating to a “neutral” rating and set a $195.00 price target for the company. in a research note on Wednesday, May 2nd. Bank of America downgraded shares of Cummins from a “buy” rating to a “neutral” rating and set a $154.00 price target for the company. in a research note on Thursday, May 3rd. They noted that the move was a valuation call. JPMorgan Chase & Co. lowered their price target on shares of Cummins from $176.00 to $164.00 and set a “neutral” rating for the company in a research note on Tuesday, April 10th. Mizuho began coverage on shares of Cummins in a research note on Friday, June 29th. They issued a “neutral” rating and a $150.00 price target for the company. Finally, TheStreet raised shares of Cummins from a “c+” rating to a “b” rating in a research note on Tuesday, May 1st. Three analysts have rated the stock with a sell rating, eighteen have issued a hold rating and five have given a buy rating to the stock. Cummins currently has a consensus rating of “Hold” and a consensus target price of $167.52. Read more …

8 Great Dividend Stocks Yielding 8% or More


High-yield dividend stocks typically play a vital role for investors planning for retirement. However, like many things in life, there is no such thing as a free lunch when it comes to income plays.

Many of the highest-yielding dividend stocks are too good to be true. Their high yields simply reflect a higher risk profile and an unsustainable dividend that will be put on the chopping block in the future. For investors living off dividends in retirement, that’s a disaster just waiting to happen.

As a result, conservative income investors would do well to steer clear of most stocks with dividend yields well above 6%.

Today, we’ll review eight dividend stocks that sport a dividend yield of at least 8%. These companies maintained their payouts during the financial crisis, and they appear poised to continue delivering generous dividends over at least the short- to medium-term.


To be clear, these are still “reach” candidates. They need to be approached with caution. Only more aggressive income investors who are willing to tolerate higher risk should consider these stocks. But in moderation, they could do well as a smaller part of a will-diversified dividend portfolio.




In case you interested of stock analysis of other bloggers, click on link below:



Analysis Collection

This Dividend Growth Stock Appears 18% Undervalued Right Now

Welcome back to the Valuation Zone, where we hunt for well-valued dividend growth stocks hiding in the forest of stocks that sell on o...